However, more recently, a pilot report from a phase I trial of CD123-CAR-T cells in 12 relapsed/refractory AML patients (NCT03766126) showed that only 25% achieved a clinical response [67] (Table 2). Here, IL3RA is linked to acute myeloid leukemia.